(Albany, New York)- 5th Sep 2026, The market dynamics for Chondrosarcoma are witnessing steady growth driven by increasing detection rates, advances in imaging and diagnostic sensitivity, growing understanding of the molecular drivers of the disease, and the significant unmet need for effective systemic therapies. Additionally, the development of promising targeted therapies such as Ivosidenib and INBRX-109 (Ozekibart), along with increasing focus on IDH1/2 mutations, EZH2 inhibition, and DR5-targeted approaches, is expected to further propel the Chondrosarcoma market during the forecast period.
DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Chondrosarcoma Market Insights, Epidemiology and Market Forecast – 2036.” This comprehensive report provides an in-depth understanding of Chondrosarcoma, including historical and forecasted epidemiology, market trends, treatment scenarios, patient burden, and competitive landscape across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
Key Takeaways from the Chondrosarcoma Market
The market size for Chondrosarcoma in the leading markets is expected to grow significantly by 2036.
The 7MM Chondrosarcoma market was approximately USD 15 million in 2025 and is projected to grow at a 16% CAGR during 2026–2036.
According to DelveInsight’s estimates, the total incident cases of Chondrosarcoma in the 7MM were approximately 2,300 in 2025.
Chondrosarcoma primarily affects adults and is the second most common primary solid tumor of bone after osteogenic sarcoma.
In 2025, conventional Chondrosarcoma accounted for approximately 80% of all Chondrosarcoma cases, making it the most prevalent subtype.
Chondrosarcoma is categorized into Grades I, II, III, and IV, with the majority of cases falling within Grade II.
IDH mutations are found in approximately 50–70% of Chondrosarcoma cases, making IDH-targeted therapies an important area of therapeutic development.
In 2025, the United States accounted for the largest Chondrosarcoma market size among the 7MM, with approximately USD 10 million in market revenue.
There are currently no approved drugs specifically for the treatment of Chondrosarcoma, creating significant unmet medical needs and opportunities for emerging targeted therapies.
Surgery remains the mainstay of treatment, while radiotherapy and chemotherapy have limited effectiveness, particularly in conventional Chondrosarcoma.
Ivosidenib, developed by Servier, is being evaluated in a Phase III study for patients with IDH1-mutant conventional Chondrosarcoma, targeting a genetically defined patient population with significant unmet need.
INBRX-109 (Ozekibart), developed by Inhibrx, is a DR5 agonist antibody currently being evaluated in a potentially registration-enabling Phase II trial for Chondrosarcoma.
Leading Chondrosarcoma companies, including Servier, Inhibrx, and others, are actively developing innovative therapies expected to transform the Chondrosarcoma treatment landscape over the coming years.
Promising Chondrosarcoma therapies in clinical development include Ivosidenib and INBRX-109 (Ozekibart).
Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/chondrosarcoma-market
Key Factors Driving the Chondrosarcoma Market
Rising Disease Detection and Diagnosis
Increased detection rates supported by advanced imaging and improved diagnostic sensitivity are contributing to higher reported cases of Chondrosarcoma. The use of X-rays, CT scans, MRI scans, and biopsy enables clinicians to visualize tumors, assess their extent, confirm diagnosis, and determine tumor grade.
Emergence of Targeted Therapies
Research into molecularly targeted therapies is creating new opportunities in Chondrosarcoma treatment. IDH1/2 inhibitors such as Ivosidenib, EZH2 inhibitors, and DR5-targeted agents such as INBRX-109 are being developed to address specific biological mechanisms involved in tumor development.
Growing Focus on IDH-mutant Chondrosarcoma
The high frequency of IDH mutations in Chondrosarcoma has created a strong rationale for developing mutation-specific treatments. The advancement of Ivosidenib into Phase III clinical development represents an important step toward targeted treatment for patients with IDH1-mutant disease.
Significant Unmet Need for Effective Systemic Therapy
Surgery remains the primary curative approach, while conventional Chondrosarcoma is generally resistant to chemotherapy and radiotherapy. The absence of effective systemic therapy for advanced disease and limited treatment options for aggressive and metastatic cases create substantial opportunities for novel therapies.
Chondrosarcoma Competitive Landscape
The Chondrosarcoma treatment landscape is primarily centered on surgical management, with the type, grade, and location of the tumor determining treatment and prognosis. Wide compartmental tumor resection remains the principal curative treatment, while curettage, radical resection, and amputation may be considered depending on tumor characteristics.
Radiotherapy and chemotherapy have limited effectiveness in conventional Chondrosarcoma because of the disease’s resistance to these approaches. Chemotherapy may have a role in selected aggressive subtypes, particularly dedifferentiated Chondrosarcoma, where regimens based on doxorubicin, cisplatin, or ifosfamide may be considered.
The emerging landscape is increasingly focused on targeted approaches. Ivosidenib, developed by Servier, is an oral IDH1 inhibitor being evaluated in a Phase III clinical trial for patients with locally advanced or metastatic conventional Chondrosarcoma harboring an IDH1 mutation.
INBRX-109 (Ozekibart), developed by Inhibrx, is a tetravalent DR5 agonist antibody designed to induce tumor cell death through efficient DR5 receptor clustering. The therapy is currently being evaluated in a potentially registration-enabling Phase II trial in Chondrosarcoma.
These emerging targeted therapies are expected to further reshape the Chondrosarcoma treatment landscape over the forecast period.
Discover more about therapies set to grab major Chondrosarcoma market share @ Chondrosarcoma Treatment Landscape
Recent Developments in the Chondrosarcoma Market
In October 2025, Inhibrx announced positive data from the INBRX-109 (Ozekibart) registration-enabling trial in patients with advanced or metastatic, unresectable Chondrosarcoma. Key data and milestone events were expected in 2026.
In January 2025, Servier announced an update to its Phase III program evaluating TIBSOVO (Ivosidenib) in IDH1-mutated cancers. The first patient had been enrolled in the CHONQUER study, a pivotal Phase III clinical trial evaluating Ivosidenib versus placebo in patients with IDH1-mutated conventional Chondrosarcoma.
What is Chondrosarcoma?
Chondrosarcoma is a group of locally aggressive or malignant tumors that produce a cartilaginous matrix. It is the most common sarcoma of bone in patients above the age of 20 and predominantly affects individuals in the fourth to sixth decades of life.
Chondrosarcoma most commonly develops in the pelvic bones, followed by the femur, humerus, and ribs. The disease may be classified as primary or secondary, depending on whether the tumor develops de novo or arises from a preexisting benign cartilage neoplasm.
The disease can be categorized into different grades based on tumor characteristics and aggressiveness. Grade II represents the majority of cases, while aggressive subtypes may demonstrate local recurrence and metastatic progression.
Diagnosis involves a combination of medical history, physical examination, X-rays, CT scans, MRI scans, and biopsy. Tissue obtained through biopsy is examined by a pathologist to confirm the diagnosis and determine tumor grade. Staging assessments may subsequently be conducted to evaluate disease spread.
Treatment depends on tumor type, grade, and location. Surgery is the primary treatment, while chemotherapy and radiotherapy have limited roles because conventional Chondrosarcoma is generally resistant to these approaches. The development of targeted therapies addressing molecular abnormalities represents an important area of ongoing research.
Chondrosarcoma Epidemiology Segmentation
The Chondrosarcoma epidemiology section provides insights into the historical and current Chondrosarcoma patient pool and forecasted trends across the seven major markets. The Chondrosarcoma market report provides epidemiological analysis for the study period 2022–2036, segmented into:
Total Incident Cases of Chondrosarcoma
Primary Incident Cases of Chondrosarcoma
Grade-specific Incident Cases of Chondrosarcoma
Mutation-specific Incident Cases of Chondrosarcoma
Stage-specific Incident Cases of Chondrosarcoma
Patient Burden Assessment
Scope of the Chondrosarcoma Market Report
Therapeutic Assessment: Current treatment approaches and emerging therapies for Chondrosarcoma
Chondrosarcoma Market Dynamics: Key market forecast assumptions, pricing trends, analogue assessment, therapy uptake, and market outlook
Key Companies: Servier, Inhibrx, and others
Key Therapies: Ivosidenib, INBRX-109 (Ozekibart), and others
Competitive Intelligence Analysis: SWOT Analysis and Conjoint Analysis
Unmet Needs, KOL’s Views, Analyst’s Views, Chondrosarcoma Market Access and Reimbursement
To know more about Chondrosarcoma companies working in the treatment market, visit @ Chondrosarcoma Clinical Trials and Therapeutic Assessment
Table of Contents
Chondrosarcoma Market Report Introduction
Executive Summary for Chondrosarcoma
Key Events of Chondrosarcoma
Epidemiology and Market Methodology of Chondrosarcoma
Chondrosarcoma Market Overview at a Glance
Clinical Landscape Analysis
Chondrosarcoma Background and Overview
Types of Chondrosarcoma
Molecular Classification of Chondrosarcoma
Causes
Signs and Symptoms
Diagnosis
Differential Diagnosis
Diagnostic Algorithm
Diagnostic Guidelines
Chondrosarcoma Epidemiology and Patient Population
Country-Specific Patient Population of Chondrosarcoma
Chondrosarcoma Current Treatment and Medical Practices
Chondrosarcoma Unmet Needs
Chondrosarcoma Emerging Therapies
Chondrosarcoma Market Outlook
Country-Wise Chondrosarcoma Market Analysis (2022–2036)
Chondrosarcoma Market Access and Reimbursement of Therapies
Chondrosarcoma Market Drivers
Chondrosarcoma Market Barriers
Chondrosarcoma Appendix
Chondrosarcoma Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
